July 2017 P&T Updates
|
|
- MargaretMargaret Byrd
- 2 years ago
- Views:
Transcription
1 July 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives ALUNBRIG 3 2 DUPIXENT Pharmacy tablets per day, 30 day One-week auth for QL of 3 syringes per 28 Remainder of the 6 month auth duration, QL of 2 syringes per 28 Then, 2/28 Elidel*, topical prednisone, prednisolone EUCRISA 3 No 2 No - prednisolone, prednisone ISENTRESS HD 2 No 2 No 2 tablets per day - RILUZOLE 1 No 1 No No - none RYDAPT 3 2 STIVARGA 3 2 AML: 56 capsules per 21 SM: 112 capsules per tablets per 28 Systemic Mastocytosis: imatinib 1 No 1 No No - - No 1 tablet per day Amitiza, Linzess - XERMELO 3 2 ZEJULA tablets per day, 28 day 3 tablets per day, 30 day octreotide, Somatuline Depot*
2 CHIP Tier Prior Auth ALUNBRIG 2 DUPIXENT Pharmacy 2 6 tablets per day, 30 day One-week auth for QL of 3 syringes per 28 Remainder of the 6 month auth duration, QL of 2 syringes per 28 Alternatives Elidel*, prednisone, prednisolone Then, 2/28 topical EUCRISA 2 No - prednisolone, prednisone ISENTRESS HD 2 No 2 tablets per day - RILUZOLE 2 No No - none AML: 56 capsules per 21 RYDAPT 2 SM: 112 capsules per 28 Systemic Mastocytosis: imatinib STIVARGA 2 84 tablets per 28-2 No No tablet per day Amitiza, Linzess XERMELO 2 3 tablets per day, 28 day octreotide, Somatuline Depot* ZEJULA 2 3 tablets per day, 30 day
3 GHP Family GHP Family Tier Prior Auth Alternative(s) ALUNBRIG Brand 6 tablets daily Xalkori*, Alcensa*, Zykadia* ATOMOXETINE Generic No 10 mg, 100 mg, 40 mg, 60 mg, 80 mg one capsule daily, 18 mg two capsules daily, 25 mg three capsules daily DUPIXENT Brand 2 syringes per 28 EUCRISA Brand No - Methylphenidate, Methylphenidate ER, Amphetamine Salt Combo, Amphetamine- Dextroamphetamine, Amphetamine- Dextroamphetamine ER, Guanfacine ER tacroliumus ointment, Elidel* tacroliumus ointment, Elidel* FOSRENOL PACKETS Brand No No - Fosrenol Tablets, Renagel ISENTRESS HD Brand No two tablets daily Isentress Tablet, Isentress Chewable Tablet LINZESS Brand No - Amitiza* OCTREOTIDE Generic No No - e RILUZOLE Generic No No - e RYDAPT Brand AML - 56 capsules per 21, SM capsules per 28 imatinib* STIVARGA Brand 84 tablets per 28 e Generic No No - Elidel* one tablet daily Amitiza*, Linzess* XERMELO Brand three tablets daily octrotide ZEJULA Brand 3 tablets daily Beginning August 15th, any prescription for greater than a 7 day supply of opioids for anyone age 17 or younger will require prior authorization. Beginning September 15th, any prescription for a greater than 14 day supply of opioids for anyone age 18 and older will require prior authorization. Beginning September 15th, any high dose of opioids will require prior authorization. Beginning November 1, new opioid quantity limits will be effective. Please call for details.
4 Geisinger Gold $0 Deductible ALUNBRIG Specialty DUPIXENT Specialty EUCRISA Brand Preferred IMFINZI Specialty ISENTRESS HD Specialty RADICAVA Specialty RYDAPT Specialty Standard Prior Auth 6 tablets/day 8 ml in Alternative(s) clobetasol, halobetasol, clobetasol, halobetasol, Bavencio*, Keytruda*, Opdivo*, Tecentriq* No 2 tablets/day Isentress 2800 mls every capsules per 28 riluzole Imatinib Generic No - - alclometasone, clobetasol, desonide, diflorasone, fluocinolone, fluticasone, halobetasol, mometasone, XERMELO Specialty ZEJULA Specialty Amitiza, Linzess 3 tablets/day octreotide, Somatuline Depot 3 tablets/day
5 Marketplace Tier Prior Auth ALUNBRIG 5 DUPIXENT Pharmacy 5 6 tablets per day, 30 day One-week auth for QL of 3 syringes per 28 Remainder of the 6 month auth duration, QL of 2 syringes per 28 Alternatives Elidel*, topical prednisone, prednisolone Then, 2/28 EUCRISA 4 No - prednisolone, prednisone ISENTRESS HD 3 No 2 tablets per day - RILUZOLE 2 No No - none RYDAPT 5 AML: 56 capsules per 21 SM: 112 capsules per 28 Systemic Mastocytosis: imatinib STIVARGA 5 84 tablets per 28-2 No No tablet per day Amitiza, Linzess XERMELO 5 3 tablets per day, 28 day octreotide, Somatuline Depot* ZEJULA 5 3 tablets per day, 30 day
May 2017 P&T Updates
May 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives 6 ml per AMPYRA 3 2 2 tablets per day, 30 day BYDUREON 3 2 4 vials per 28 days 5 mcg pen: 1.2 ml per
March 2018 P & T Updates
March 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AURYXIA 3 2 12 tablets per BAXDELA TABLETS 3 2 2 tablets per Depending on your specific benefits and in which
March 2017 P&T Updates
March 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth DICLEGIS 3 No 2 No Yes EMVERM 2 No 2 Yes Yes Detailed s 4 tablets per day, 9 month supply per year Pinworms: 1 tablet
Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
November 2018 P & T Updates
November 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AIMOVIG 3 2 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY 3 2 4.5 ml
Neighborhood Medicaid Formulary Changes: June 2017
Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
The safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
January 2018 P & T Updates
January 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional BEVYXXA 3 No 2 BOSULIF 3 2 * Indicates prior authorization (PA) or step (ST) Depending on your specific benefits and in
CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
Eucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
Eucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
Step Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
Rationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs)
BLUE SHIELD OF CALIFORNIA FIRST QUARTER 2015 FORMULARY AND MEDICATION POLICY UPDATES EFFECTIVE MARCH 19, 2015 The Blue Shield of California (BSC) Pharmacy and Therapeutics (P&T) Committee, consisting of
Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
San Francisco Health Plan (SFHP)
San Francisco Health Plan (SFHP) The following changes to SFHP formulary and prior authorization criteria were reviewed and approved by the SFHP Pharmacy and Therapeutics (P&T) Committee on 04/18/2018.
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION
LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17
Quarterly pharmacy formulary change notice
Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics
1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 1/1/19, Cigna is making changes to our formularies that may impact medication coverage for customers at your pharmacy. We have included a
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen
May 2016 P & T Updates
Commercial Triple Tier 4th Tier Applicabl e Traditional Detailed s 2 films - DESCOVY 2 2 1 tablet NARCAN 2 2 ODEFSEY 2 2 1 tablet REPATHA 2 2 HoFH: 3 ml per 28 ROSUVASTATIN 1 1 - UPTRAVI 3 2 - Alternatives
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE February 18, 2015 SUBJECT EFFECTIVE DATE January 21, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 21, 2015 Pharmacy Services Vincent D. Gordon, Deputy
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.PHAR.336 Effective Date: 05.01.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
Oral Oncology Agents. August 2017 Update. SGLT-2 Category Update. Removal of Medical Foods
SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE SEPTEMBER 2017 ISSUE 4 HELPFUL NUMBERS FOR PROVIDERS CVS: 1-888-512-8935 Primary: 004336 Secondary Commercial: 013089 Secondary
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
Cerebral Stimulant and ADHD Drugs Prior Authorization Request
Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization
Pharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
WellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/21/2017.
Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
2018 Medicare Part D Formulary Change
2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy
ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019
Step Therapy Date Effective: April 1, 2019 ANTICONVULSANTS APTIOM TABLET 200 MG ORAL APTIOM TABLET 400 MG ORAL APTIOM TABLET 600 MG ORAL APTIOM TABLET 800 MG ORAL BANZEL SUSPENSION 40 MG/ML ORAL BANZEL
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard)
ELEVATE Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard) P&T/Formulary Committee Actions 4Q 2017 (Effective January 1, 2018) Marketplace Standard
Aetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
2018 Medicare Part D Formulary Change
2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy
Reason for change. Recently approved. Recently approved. Recently approved. Recently approved. Recently updated. Recently approved.
2017 Formulary Change Notice Please note these changes to your 2017 List of Covered Drugs Drug name (medication) Rubraca Aprepitant Onivyde Oseltamivir Restasis Xiidra Daptomycin Selzentry Linzess Butalb/APAP/caff
Effective for all members on August 1, 2017
August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List
**CRITERIA UNDER CMS REVIEW**
**CRITERIA UNDER CMS REVIEW** ANTICONVULSANTS APTIOM TABLET 200 MG APTIOM TABLET 400 MG APTIOM TABLET 600 MG APTIOM TABLET 800 MG BANZEL SUSPENSION 40 MG/ML BANZEL TABLET 200 MG BANZEL TABLET 400 MG BRIVIACT
Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/23/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
2018 CareOregon Advantage Part D Formulary Changes
2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD
AD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
2017 Formulary Addendum Notice of Change
2017 Formulary Addendum Notice of Change (Prescription Drug Plans) WellCare Prescription Insurance, Inc. WellCare Classic (PDP) WellCare Extra (PDP) This is a listing of the changes that have occurred
Step Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
Central Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
2017 Formulary Addendum Notice of Change (Prescription Drug Plans)
2017 Formulary Addendum Notice of Change (Prescription Drug Plans) WellCare Prescription Insurance, Inc. WellCare Classic (PDP) WellCare Extra (PDP) This is a listing of the changes that have occurred
2017 Formulary Addendum Notice of Change
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) WellCare Health Plans WellCare Access (HMO SNP), WellCare Liberty (HMO SNP), WellCare Reserve (HMO), WellCare Rx (HMO), WellCare Select
Dupixent (dupilumab)
Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
Drug Formulary Update, January 2013
Drug Formulary Update, January 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota
UPDATE Ohana QUEST Integration Medicaid
UPDATE Ohana QUEST Integration Medicaid Preferred Drug List June 29, 2015 Dear Provider: At the June 04, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes
San Francisco Health Plan (SFHP)
San Francisco Health Plan (SFHP) The following changes to SFHP formulary and prior authorization criteria were reviewed and approved by the SFHP Pharmacy and Therapeutics (P&T) Committee on 07/18/2018.
Health Partners Medicare Prime 2019 Formulary Changes
Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes
Big Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
Emblem Medicaid 3Q18 Formulary Updates
ALKERAN 2 MG TABLET Removed from Formulary 7/9/2018 AMITIZA 24 MCG CAPSULES Removed from Formulary 7/9/2018 AMITIZA 8 MCG CAPSULE Removed from Formulary 7/9/2018 avo cream topical emulsion Removed from
Your prescription benefit updates Formulary Updates - Effective January 1, 2019
Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will
ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
Alprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
HMO and PPO Updates September Commercial Results
HMO and PPO Updates September 2013- Commercial Results Triple Tier Formular y 4th Tier Applicable Traditiona l Quantit y Limit Alternatives SIRTURO 3 2 First fill: 56 tablets Subsequent fills: 24 tablets
The Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
The Latest Prescription Trends for Controlled Prescription Drugs
The Latest Prescription Trends for Controlled Prescription Drugs September 1, 2015 Christopher M. Jones PharmD, MPH Senior Advisor Office of Public Health Strategy and Analysis Office of the Commissioner
Health New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015.
April 17, 2015 FULLY FUNDED PLANS ONLY RE: Semi-Annual Notice of Changes Dear HNE Member: Health New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015. I have
Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information
Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Freedom Plan (HMO SNP) H5087-001 This is a listing of the changes that have occurred in our formulary.
Pharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
2017 Formulary Addendum Notice of Change
017 Formulary Addendum Notice of Change (Medicare Advantage Plans) WellCare Health Plans WellCare Choice (HMO), WellCare Essential (HMO-POS), WellCare Value (HMO) This is a listing of the changes that
PHARMACY AND THERAPEUTICS COMMITTEE August 2016
PHARMACY AND THERAPEUTICS COMMITTEE August 2016 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on August 23, 2016. The following are the recommendations for the drugs
Pharmacy Formulary Updates for January 2019
Pharmacy Formulary Updates for January 2019 To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMA_10.11.7 Effective Date: 07.16 Last Review Date: 04.18 Line of Business: Cenpatico Medicaid Arizona Revision Log See Important Reminder at the end of this policy
2017 Step Therapy (ST) Criteria
2017 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
2018 Formulary Update
MEDICARE ADVANTAGE BlueShield of Northeastern New York 2018 Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January 2018. This
Update to HMO Drug Formulary Tier Definitions. February 8, 2018
Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works
OH Gold PPO /50 Metallic Level: Gold. $500 copay per admission after deductible. T1A-$3 copay plus 30% T1-$10 copay plus 30%
OH Gold PPO 1000 100/50 Metallic Level: Gold OH Gold PPO 1000 80/50 Metallic Level: Gold Member benefits* Network Care Out-of-network care Network Care Out-of-network care Calendar year $1,000/$2,000 $3,000/$6,000
Topical Immunomodulators
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Topical Immunomodulators Clinical Edit Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03%
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)
207 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Plus Plan (HMO) H5087-002, H5087-07 This is a listing of the changes that have occurred in our formulary.
ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018
Step Therapy Requirements Effective April 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone
ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018
Step Therapy Requirements Effective June 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone
ALLERGIC RHINITIS-NASAL
ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step
You ll find the most up-to-date comprehensive version of our formulary on our website, Click on Drug Finder.
3/1/2018 Medicare Part D Formulary Change In an effort to cover the most needed, cost-effective prescriptions, the AlohaCare Advantage Plus (HMO SNP) Formulary is updated monthly. The following are drugs
FlexRx 6-Tier. SM Pharmacy Benefit Guide
FlexRx 6-Tier SM Pharmacy Benefit Guide Welcome to FlexRx The AllWays Health Partners FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many
DRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde
WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High
Pharmacy Benefit Determination Policy
Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Best Plan (HMO) H5087-005 This is a listing of the changes that have occurred in our formulary. Please
Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
2017 Medicare Part D Formulary Change
2017 Medicare Part D Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy restrictions
2019 Formulary Update
MEDICARE ADVANTAGE BlueShield of Northeastern New York Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January. This document
Kentucky Medicaid will incorporate the following changes to its PDL on June 11, 2014:
Fee-For-Service Pharmacy Provider Notice #179 April Pharmacy Updates May 22, 2014 11013 W. Broad Street Glen Allen, VA 23060 Dear Kentucky Medicaid Provider: Please be advised that the Department for Medicaid
Big Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For